Top Medical News
Roshini Claire Anthony, 3 days ago

More patients initiating or escalating anti-hypertensive treatment achieved their blood pressure (BP) goals when taking a once-daily pill containing low doses of three antihypertensive medications (telmisartan, amlodipine, and chlorthalidone) compared with those on usual care, according to the TRIUMPH* study conducted in Sri Lanka.

3 days ago
An association exists between concurrent diabetic retinopathy (DR) and an increased risk of incident Parkinson’s disease (PD), reports a recent study.
Jackey Suen, 5 days ago

The use of fingolimod was associated with a lower rate of relapse and less accumulation of lesions on MRI compared with interferon beta-1a in paediatric patients with relapsing multiple sclerosis (MS), the phase III PARADIGMS study has shown.

15 Sep 2018
New drug applications approved by US FDA as of 1 - 15 September 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
14 Sep 2018
The use of antidepressant drugs in pregnant women taking antiepileptic drugs (AEDs) does not appear to contribute to a significant increase in the risk of congenital malformations, as well as affect seizure control, a study has found.
13 Sep 2018
Excessive daytime sleepiness appears to increase the long-term risk of amyloid β (Aβ) deposition, a recent study has shown.
12 Sep 2018
Among obese and overweight adults with type 2 diabetes mellitus, women appear to be less likely than men to develop mild cognitive impairment, independent of traditional risk factors, a recent study has shown.
Special Reports
04 May 2018
Multiple sclerosis (MS) is one of the most common neurological disorders – affecting over 2.3 million people globally – and it is the leading cause of nontraumatic disability in young adults. However,the availability of supportive resources and services for people with MS is scarce in many regions of the world. In Malaysia, the prevalence of MS is estimated at 2-3/100,000; the current Malaysian clinical practice guidelines on the management of MS recommend disease modifying agents, such as interferon-β and teriflunomide, as first-line therapeutic agents. In this article, Dr Singer - in partnership with Sanofi and the Malaysian Society of Neurosciences - shares his insights into managing MS dynamically, highlighting the importance of early intervention in improving patient outcomes.
01 May 2018
CoQ10 isn't as popular as vitamin C or B in our daily lives but it's time to have a closer look at this vital nutrient.
13 Dec 2017
At the Schwabe-Menarini lunch symposium of the 11th International Congress of the Asian Society AgainstDementia (ASAD) 2017 held in Bangkok, Thailand, Professor Ralf Ihl highlighted the role of standardized Gingko biloba extract EGb 761® for the treatment of patients with behavioural and psychological symptoms of dementia (BPSD). Meanwhile, Associate Professor Nagaendran Kandiah presented clinical findings on the association between cerebrovascular disease (CVD) and dementia, and emphasized the role of EGb 761® in the management of dementia with CVD.
01 Jul 2017
At the recent launch of Nurofen® Express by Reckitt Benckiser Malaysia, Ms Joyce McSwan spoke on the importance of managing tension-type headache (TTH), highlighting the roles of drug and non-drug approaches in improving treatment outcomes.
Roshini Claire Anthony, 22 Nov 2016

Blood pressure lowering medications and statins do not prevent cognitive and functional decline in elderly patients, according to results of the HOPE-3 trial* presented at the Scientific Sessions of the American Heart Association (AHA 2016) held recently in New Orleans, Louisiana, US.

Dr. Rose Zhao-Wei Ting, 16 Nov 2016
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
24 Aug 2016

Roshini Claire Anthony spoke with Adjunct Associate Professor Gamaliel Tan, head and senior orthopaedic consultant at Ng Teng Fong Hospital in Singapore, on how GPs can help diagnose and treat lower back pain.

Conference Reports
Roshini Claire Anthony, 15 Aug 2018

Changes in cardiometabolic factors such as body mass index (BMI), glucose levels, and blood pressure (BP) may signify dementia risk up to 14 years pre-diagnosis, with management of these risk factors potentially preventing dementia, according to a French population-based study presented at the Alzheimer’s Association International Conference (AAIC 2018).

Audrey Abella, 15 Aug 2018
Supervised aerobic-strength training improved cognitive and motor functions among elderly individuals with mild cognitive impairment (MCI), according to studies presented at AAIC 2018.
Elvira Manzano, 14 Aug 2018
A new study reinforces the gut-brain connection in Alzheimer’s disease (AD), untangling the complex interplay between gut and brain health that could potentially lead to new therapies targeted at manipulating the gut microbiome to treat AD.
Audrey Abella, 10 Aug 2018
Incorporating virtual reality (VR) modules into the ‘Bringing Art to Life’ (BATL) service learning programme provided participants with a greater understanding of people with Alzheimer’s disease (AD) and other dementias (PWDs), according to a presentation at the Alzheimer’s Association International Conference (AAIC 2018).

Pearl Toh, 03 Aug 2018
The novel oral BACE* inhibitor elenbecestat showed an acceptable safety profile and was generally well tolerated in patients with mild cognitive impairment (MCI)-to-moderate Alzheimer’s disease (AD), with additional benefit of reducing amyloid load in the brain, a new study finds.
Pearl Toh, 31 Jul 2018
There is no evidence that hormone replacement therapy (HRT) may affect cognitive ability, especially when it is initiated early on during menopausal transition, according to studies presented at AAIC 2018, suggesting a need to rethink the long-held belief that HRT may negatively affect cognition.
Pearl Toh, 30 Jul 2018
The synthetic cannabinoid nabilone significantly improves noncognitive symptoms, in particular agitation, in people with moderate-to-severe Alzheimer's disease (AD), suggests a small randomized controlled trial.